Applications for Cancer Research

Rockland and The Scientist assembled a panel of experts to discuss the importance of epigenetic profiling in cancer research, and to explore how this knowledge can be applied to develop targeted therapies. Topics to be covered include: • The role of epigenetic dysregulation of long, non-coding RNAs (lncRNAs) in tumorigenesis • Epigenetic engineering as a means for studying aberrant or deleterious modifications Complex genetic and epigenetic modifications underlie the initiation and progression of cancer. Scientists are attempting to unravel the epigenome to gain an understanding of the interplay between oncogenesis and epigenetics. To explore these issues, The Scientist has assembled a panel of experts to discuss the importance of epigenetic profiling in cancer research, and to explore how this knowledge can be applied to develop targeted therapies. With speakers, Dr. Ahmad M. Khalil, Assistant Professor of Genetics and Genome Sciences at Case Western Reserve University School of Medicine and Dr. Lanlan Shen, Associate Professor at Baylor College of Medicine. Established in 1962, Rockland Immunochemicals Inc. is a global biotechnology company manufacturing leading edge research tools for basic, applied and clinical research in functional genomics, gene therapy and drug discovery markets. Rockland is a privately held company which operates a manufacturing facility with antibody and protein production capabilities located near Philadelphia, Pennsylvania, USA. Global markets are supported through a highly specialized network of key distributors. Our laboratories consist of over 60,000 square feet, producing antibodies and antibody-based tools that are used to help define mechanisms underlying cell function and disease.

• #science_technology
• #cancer_research
• #epigenetics_modifications
• #epigenome
• #epigenetics
• #cancer_therapies
• #dna